Life Sciences Tools and Services

R&G Pharma

R&G Pharma released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 218.09 M, actual EPS CNY 0.24

R&G Pharma FY2026 Q1 Earnings Release Scheduled for April 28 After-Market BJT

R&G Pharma released FY2025 earnings on March 27 After-Market (BJT), actual revenue CNY 851.01 M (forecast CNY 767 M), actual EPS CNY 1.43 (forecast CNY 1.46)

R&G Pharma released FY2025 Q4 earnings on March 27 After-Market BJT, actual revenue CNY 243.64 M, actual EPS CNY 0.4294

R&G Pharma to Release FY2025 Annual Earnings on March 28 After-Market (BJT), Forecast Revenue CNY 767 M, EPS CNY 1.46

R&G Pharma released FY2025 9 Months Earnings on October 28 During-Market (BJT), Actual Revenue CNY 607.37 M, Actual EPS CNY 1.001

R&G Pharma released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 227.71 M, actual EPS CNY 0.3599

R&G Pharma FY2025 Q3 Earnings Release on October 29 During-Market (BJT)

R&G Pharma released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 379.66 M, actual EPS CNY 0.64

R&G Pharma released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 206.82 M, actual EPS CNY 0.3711

R&G Pharma to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Pacific Research Analysts Maintain Buy Rating on Nuostar

NHS and NMPA Issue Measures to Support Innovative Drug Development

Norther Repurchased Shares as Planned

Norther Pharmaceutical Faced Obstacle in IPO

Northage Receives Notice of Civil Rehearing Case from Supreme Court

Chinese Innovative Pharma Companies Achieve Globalization Through Licensing-Out

NMPA Seeks Public Opinion on Clinical Trial Optimization for Innovative Drugs

Noshig Secretary Responds to No In-House Innovative Drug Development

Noseke Releases 2025 Q1 Financial Report

688710

159859

688105

301333

Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to Semaglutide

Wallstreetcn

INNOSTAR

Tianhong CNI BIOMEDICINE ETF

Vazyme

Novo Nordisk AS

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

301230

000516

300404

688246

AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

IMIC

BOJI CRO

GOODWILL

R&G Pharma announced that the closing price increase deviation of the company's stock exceeded 30% cumulatively over three consecutive trading days on October 29, 2025, October 30, 2025, and October 31, 2025. There are no corrections or supplements needed for the information previously disclosed by the company, and there have been no significant changes in the company's operating conditions or internal and external operating environment recently. The company, its controlling shareholders, and actual controllers do not have any significant matters related to the company that should be disclosed but have not been disclosed

Zhitong

R&G Pharma: Abnormal fluctuations in stock trading

According to the Zhitong Finance APP, R&G Pharma released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 607 million yuan, a year-on-year increase of 8.09%. The net profit attributable to shareholders of the listed company was 95.5668 million yuan, a year-on-year increase of 13.21%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 81.3334 million yuan, a year-on-year increase of 22.47%. The basic earnings per share were 1 yuan

R&G Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 95.5668 million yuan, an increase of 13.21%

R&G Pharma plans to implement an employee stock ownership plan in 2025, with a total funding amount not exceeding 15 million yuan. The funding sources include the company's reward fund and other legal means. The planned stock scale is not more than 385,800 shares, with a repurchase price of 38.88 yuan per share, and a duration of 36 months

R&G Pharma plans to launch an employee stock ownership plan in 2025 with a total funding not exceeding 15 million yuan

R&G Pharma announced that in the first half of 2025, operating revenue will be 380 million yuan, a year-on-year increase of 0.18%. Net profit will be 61.1161 million yuan, a year-on-year increase of 4.45%

R&G Pharma: Net profit of 61.1161 million yuan in the first half of 2025, a year-on-year increase of 4.45%

R&G Pharma announced that the company has repurchased 1.442 million shares, using a total amount of 56.0627 million yuan. The repurchase plan was approved on July 1, 2024, and is intended for the employee stock ownership plan or equity incentive. The repurchased shares account for 1.49% of the company's total share capital, with a highest transaction price of 43.15 yuan/share and a lowest transaction price of 35.06 yuan/share, and the repurchase period is within 12 months

R&G Pharma: Has repurchased 1.442 million shares with a total fund amount of 56.0627 million yuan

R&G Pharma Technology Co., Ltd. encountered malicious extortion during the listing application process. The related criminal gang obstructed the company's listing through illegal means and repeatedly demanded large sums of money. The company was forced to compromise and make payments to protect the rights of its shareholders and employees. It has now reported to the public security authorities, and Zhong Dafang has been criminally detained, while his accomplice Chen has fled abroad

R&G Pharma: During the company's IPO application process in 2020, it encountered malicious extortion

R&G Pharma recently issued a statement claiming that some media and self-media accounts have published false reports about R&G Pharma and its actual controller Wu Jie without investigation, seriously affecting the company's image. Since its establishment in 2008, R&G Pharma has adhered to the principles of scientific rigor, but encountered malicious extortion during its listing application in 2020. Zhong Dafang and others obstructed the listing process through illegal means and demanded huge sums of money. Zhong Dafang has been criminally detained, while Chen has fled abroad. R&G Pharma condemns the relevant media for distorting the facts and reserves the right to hold them accountable, stating that justice will ultimately be served

R&G Pharma statement: False reports affect corporate image

R&G Pharma announced that the company recently received a civil application for retrial from the Supreme People's Court, regarding the "Notice of Response to Lawsuit." Zhong Dafang is dissatisfied with the second-instance civil judgment made by the Beijing High People's Court and has applied for a retrial to the Supreme People's Court. As of the date of this announcement, the case has been filed for retrial review, and the company will fulfill its information disclosure obligations in a timely manner based on the final review results

R&G Pharma: Progress of lawsuits involving the company, its subsidiaries, and actual controllers

R&G Pharma(301333.SZ)